Answers are grounded in this paper and cite their sources.
Background Multiple sclerosis (MS) causes inflammatory demyelination, axonal injury, and synaptic pathology, culminating in progressive neurodegeneration. Sephin1, an integrated stress response (ISR) modulator, reduces clinical severity in experimental autoimmune encephalomyelitis (EAE) and protects spinal cord oligodendrocytes, myelin, and axons. Yet EAE clinical scores primarily measure motor disability, leaving unresolved whether Sephin1 preserves function in a defined central nervous system circuit. Here, we tested whether Sephin1 protects the visual pathway, a clinically relevant and functionally accessible circuit affected in MS. Methods EAE was induced in C57BL/6J mice using MOG 35–55 immunization. Sephin1 or vehicle was administered prophylactically beginning 7 days post-induction through peak disease, or therapeutically beginning at clinical onset either through chronic disease or for 7 days. Visual function was assessed by recording the optomotor response, pattern-stimulated visual evoked potentials (pVEP), and pattern electroretinography (PERG). Retina, optic nerve, and lateral geniculate nucleus (LGN) pathology were assessed using immunohistochemistry and RNA in situ hybridization. Results Prophylactic Sephin1 treatment reduced EAE clinical severity and preserved visual acuity at peak disease. Sephin1 also preserved pVEP N1 amplitudes, indicating protection of visually evoked cortical response magnitude, while pVEP latency, PERG responses, and retinal ganglion cell (RGC) numbers were not significantly altered at this stage. Histologically, Sephin1 protected optic nerve myelin, oligodendrocytes, and axons. Downstream, in the LGN, Sephin1 preserved retinogeniculate axons and RGC presynaptic terminals. These protective effects occurred without detectable reductions in optic nerve CD45 + immune cell accumulation, CD3 + T-cell infiltration, astrogliosis, or inflammatory microglial responses. Sephin1-treated EAE optic nerves showed increased phosphorylation of eukaryotic translation initiation factor 2 alpha, the core ISR-initiating event, and increased transcripts of the ISR target Ddit3 , together with more cleaved caspase-3 + cells than in CFA controls. In contrast to prophylactic-to-peak disease treatment, Sephin1 initiated at clinical onset, either through chronic disease or for 7 days only, did not preserve visual acuity chronically. Similarly, continuous onset-initiated treatment did not preserve chronic RGC numbers. Conclusions Sephin1 preserves function and structure in a defined visual circuit during peak inflammatory demyelination when administered prophylactically, demonstrating circuit-level protection beyond standard EAE clinical scoring. However, onset-initiated Sephin1 treatment is insufficient to prevent chronic visual dysfunction, suggesting that ISR enhancement as a monotherapy has a limited therapeutic window in EAE-associated visual pathway injury.
No takes yet. Share an insight, caveat, or question.
Mey et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: